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Abstract High-dose capsaicin patch is effective in treat-
ment of neuropathic pain in HIV-associated neuropathy
and diabetic neuropathy. There are no studies assessing
effectiveness of high-dose capsaicin patch in treatment of
chemotherapy-induced peripheral neuropathy. We sought
to determine the effectiveness of treatment of pain asso-
ciated with chemotherapy-induced peripheral neuropathy
with high-dose capsaicin patch. Our study group consisted
of 18 patients with clinically confirmed oxaliplatin-induced
neuropathy. Baseline characteristic including underling
disease, received cumulative dose of neurotoxic agent,
neuropathic symptoms, prior treatment and initial pain
level were recorded. Pain was evaluated with Numeric
Rating Scale prior to treatment with high-dose capsaicin
and after 1.8 day and after 8 and 12 weeks after intro-
ducing treatment. Patients were divided into two groups
accordingly to the amount of neurotoxic agent that caused
neuropathy (high sensitivity and low sensitivity group).
Most frequent symptoms of chemotherapy-induced neu-
ropathy were: pain (88.89%), paresthesis (100%), sock and
gloves sensation (100%) and hypoesthesis (100%). Initial
pain level was 7.45 ± 1.14. Mean cumulative dose of
oxaliplatin after which patients developed symptoms was
648.07 mg/m2. Mean pain level after 12 weeks of treat-
ment was 0.20 ± 0.41. When examined according to high
and low sensitivity to neurotoxic agent patients with low
sensitivity had higher pain reduction, especially after
8 days after introducing treatment (69.55 ± 12.09 vs.
49.40 ± 20.34%; p = 0.02) and after 12 weeks
(96.96 ± 5.56 vs. 83.93 ± 18.59%; p = 0.04). High-dose
capsaicin patch is an effective treatment for pain associated
with chemotherapy-induced neuropathy in patients treated
with oxaliplatin. Patients with lower sensitivity to neuro-
toxic agents have better response to treatment and pain
reduction.
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Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is
frequent complication of anti-neoplastic treatment with
established frequency of 30–40% of patients undergoing
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chemotherapy [1]. It significantly reduces quality of life
and may be the cause of dose limitation or even cessation
of treatment [2]. CIPN can be induced by many
chemotherapeutics such as: taxanes, vinca alkaloids, epo-
thilone, bortezomib, thalidomide and especially platinum
agents [3]. Oxaliplatin is the most frequent agent causing
CIPN causing symptoms even after 2 years after cessation
of treatment [4]. Currently, there are many emerging con-
cepts for treatment of CIPN [5]. Treatment options that
have proven effectiveness are duloxetine [6], venlafaxine
[7] and gabapentinoids [8]. Opioids show very limited
effects [9]. Promising concepts with very limited data
consider topical menthol [10]. Fallon et al. [10] recently
described that topical menthol improves pain, walking
ability, mood and sensation in patients with CIPN. Other
concept studied by Gewandter et al. [11] considered topical
amitriptyline with ketamine, but received poor results in
comparison with placebo.
Currently, high-dose topical capsaicin patch receives
extensive attention. Capsaicin is an agonist of the transient
receptor potential vanilloid receptor (TRPV1). It inhibits
neural transmission in sensatory axons. Topical capsaicin
patch has been proven effective for post-herpetic neuralgia
[12, 13] and human immunodeficiency virus (HIV)-asso-
ciated neuropathy [14]. On the other hand, large Cochrane
Database review suggests that it should be used only as a
last resort [15]. Despite growing interest in topical high-
dose capsaicin patch in treatment of neuropathic pain, there
are no studies describing effectiveness of capsaicin on
CIPN [5]. The aim of our study is to determine the effec-
tiveness of high-dose capsaicin patch in treatment of CIPN-
associated pain.
Methods
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki, International
Conference on Harmonization of Technical Requirements
for Registration of Pharmaceuticals of Human Use (ICH)
Good Clinical Practice, current US FDA guidelines, and
local ethical and legal requirements. The study was
approved by the Institutional Review Boards of all partic-
ipating institutions. We received permission to conduct this
study from the Jagiellonian University Bioethics Commit-
tee (KBET/235/B/2014). All patients provided written
informed consent.
For the study, we qualified patients in stable state
undergoing oxaliplatin-based chemotherapy for colon
cancer who developed painful peripheral polyneuropathy,
based on clinical history and neurological examination.
The patients were asked to give their written consent before
application of high-dose 8% capsaicin patch.
Between January 2013 and February 2014, twenty-one
patients with chronic pain resulting from CIPN were
referred by medical oncologists to application of a high-
dose 8% capsaicin patch. All the patients were assessed and
qualified by a specialist in neurology and palliative medi-
cine. A questionnaire of neuropathic symptoms was used
and included questions about the presence of numbness,
tingling, pain or impaired sensory function in hands and/or
feet, clumsiness in fingers, peripheral muscular weakness
or difficulties in walking, and the patients replied with Yes
or No answers. Symptoms and signs of neuropathic pain
were evaluated including a history of sensory sensations
such as tingling, numbness, sharp, burning, shooting, or
electric-like pain, paresthesia, allodynia, hyperalgesia and
hyperpathia and motor dysfunction (foot or wrist drop,
symmetric motor weakness, difficulty buttoning a shirt or
holding a pen), myalgias or muscle cramps. Neurological
examination was performed by a neurologist. The neuro-
logical examination included motor assessment (muscle
strength in the limbs), sensory testing (examination of
touch, pinprick, cold, warmth, vibration and position sense
and testing of allodynia for dynamic and static mechanical
stimuli), testing of balance, coordination, and deep tendon
reflexes. All patients met the inclusion criteria: age
18–72 years, diagnosed chemotherapy-induced peripheral
sensory neuropathy, average pain intensity equal to or
higher than 4 at screening for at least four consecutive days
according to NRS, undamaged and non-irritated, dry skin
at the sites of pain location, informed, written consent to
participate in a clinical study. Patients were excluded when
one or more of the following criteria were met: hypersen-
sitivity to capsaicin, pregnancy, diabetes mellitus, patients
with unstable or poorly controlled hypertension or a history
of recent cardiovascular events (6 months) before starting
treatment, patients using high doses of opioids in the
treatment, patients in whom a high degree of opioid tol-
erance is suspected, patients in whom we observe lack of
response to opioid analgesics administered orally in acute
pain during the treatment procedure.
The patch application process took place in a dedicated
minor operation theater. The patients selected for the
treatment had their dynamic pain score recorded prior to
application.
The patients were given a patient information leaflet
prior to admission, and the procedure was explained and
any concerns or questions answered. Capsaicin 8% patch
was applied by a nurse and closely supervised by a
physician. Skin on the application site could not be irri-
tated, dry or intact, a topical anesthetic cream (EMLA) was
applied 1 h before Qutenza patch application. The patch,
which may be cut to shape, was used within 2 h of opening
the foil pouch. Patients may require systemic analgesic
medication or topical cooling at the site during and after
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treatment. They were encouraged to wear it for as long as
possible, but it could be removed if the pain became
intolerable. None of the adverse events occurred.
Pain evaluation
Efficacy was measured using an 11-point Numerical Rating
Scale (NRS) with 10 representing the worst pain imagin-
able and 0 representing no pain. Initial pain level was taken
before administrating capsaicin patch and after 1 and
8 days after administration and after 8 and 12 weeks after
administration of the patch.
Statistical method
Elements of descriptive statistics were used (mean, stan-
dard deviation, percentage distribution). We used v2
Pearson’s test to compare proportions. T test and Mann–
Whitney U test were used as appropriate to compare con-
tinuous variables. All statistical calculations were pre-
formed using STATISTICA 10.0 v. (Statsoft, Poland)
software for Microsoft Windows.
Results
Average pain score was 4 or above during the screening
period, over a minimum of at least four consecutive days
(using the NRS scale).
Baseline characteristics
Eighteen patients were included into the study. All the
patients received treatment according to the scheme and
were involved in the evaluation of efficacy and safety.
Among patients enrolled in the study, there were 12 women
and 6 men, with a mean age of 62 years. Mean cumulative
neurotoxic dose was 832.9 mg/m2; however, the beginning
dose after which the symptoms of polyneuropathy appeared
was 648.07 mg/m2. Average initial pain intensity was
assessed at 7.67 ± 0.51 points in the group.
Because of the symptoms of chemotherapy-induced
neuropathy in the period preceding the application of the
patch 9 people did not receive any treatment for neuro-
pathic pain. The treatment received by others is presented
in Table 1. Eighteen patients out of twenty-one finished the
complete observation. Three of the patients discontinued
their participation in the study for personal reasons.
Efficacy
In the 12-week study, pain reduction in patients whose
initial symptoms occurred after the administration of
648.07 mg/m2 of oxaliplatin was, respectively, 28% after
the first day and 84% at 12 weeks after application of the
patch. In the second group of patients in whom the
symptoms appeared after the treatment with higher cumu-
lative doses of oxaliplatin, reduction of pain was, respec-
tively, 33% after the first day and 97% after 12 weeks.
Statistical analysis of the results of the research shows a
statistical significance between the treated groups of
patients, which show as considerably higher levels of pain
Table 1 Characteristic of treated patients
Characteristics Value
Number of patients, n (%) 18 (100)
Age, years (SD) 62.67 (8.25)
Female, n (%) 12 (66.67)
Cancer location
Colon, n (%) 18 (100)
Cumulative neurotoxic dose, mg/m2 (SD) 832.9 (111.53)
Beginning of symptoms after, mg/m2 (SD) 648.07 (331.12)
Drugs prior to capsaicin
No treatment, n (%) 9 (50)
Gabapentin, n (%) 5 (27.78)
Pregabalin, n (%) 2 (11.11)
Amitriptyline, n (%) 2 (11.11)
SSRIs, n (%) 2 (11.11)
Transdermal lidocaine, n (%) 2 (11.11)
Coexisting morbidities
Hypertension, n (%) 8 (44.44)
Ischemic heart disease, n (%) 5 (27.78)
Symptoms
Pain, n (%) 16 (88.89)
Paresthesis, n (%) 18 (100.00)
Weakness, n (%) 15 (83.33)
Disequilibrium, n (%) 6 (33.33)
Dizziness, n (%) 2 (11.11)
Cramps, n (%) 3 (16.67)
Sock and gloves sensation, n (%) 18 (100.00)
Hypoesthesis, n (%) 18 (100.00)
Bathyanaesthesis, n (%) 17 (94.44)
Decreased deep tendon reflex, n (%) 18 (100.00)
Sensory ataxia, n (%) 6 (33.33)
Initial pain level 7.45 ± 1.14
Pain after 1 day, NRS, ±SD 4.95 ± 1.39
Pain after 8 days, NRS, ±SD 2.55 ± 1.14
Pain after 8 weeks, NRS, ± SD 1.20 ± 1.10
Pain after 12 weeks, NRS, ± SD 0.20 ± 0.41
WHO neuropathic score before treatment, ±SD 2.00 ± 0.65
ECOG neuropathic score before treatment, ±SD 2.35 ± 0.67
WHO neuropathic score after 12 weeks, ±SD 0.55 ± 0.51
ECOG neuropathic score after 12 weeks, ±SD 0.65 ± 0.48
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reduction after 8 days and 12 weeks for patients with the
used cumulative doses (average of 20% after 8 days and
about 14% after 12 weeks). The main measure of effec-
tiveness was reduction of pain as measured by 24-h NRS
pain assessment scale for up to 12 weeks after application
of the patch. After the application of the patch, statistically
significant reduction of pain in NRS scale was obtained,
respectively, after 8 days in the first group with symptoms
occurring\648.07 mg/m2 of oxaliplatin 3.83 and 2.25 in
the second group (p = 0.02). After 12 weeks following the
application of Qutenza patch, patients achieved a reduction
of at least 1.16 in NRS score in the first group compared
with 0.25 of the second group (p = 0.04). All the results
are presented in Table 2.
Discussion
In our study, we described efficacy and safety of high-dose
8% capsaicin patch in treatment of patients with
chemotherapy-induced peripheral neuropathy in patients
treated with oxaliplatin-based chemotherapy for colon
cancer. Total reduction of pain ranged between 84 and 97%
assessed at 12 weeks. Furthermore, we observed no
adverse events showing that high-dose capsaicin is safe and
effective way to treat CIPN.
Effectiveness of high-dose 8% capsaicin is well estab-
lished in treatment of HIV-associated neuropathy and post-
herpetic neuralgia [16]. Results of meta-analysis calculat-
ing the data from seven studies incorporating 1458 patients
showed reduction of neuropathy-related symptoms in favor
of high 8% capsaicin in comparison with low-dose cap-
saicin 0.04% patch [16]. Another meta-analysis performed
by Mou et al. [17] showed that for initial symptoms
reduction of[30% occurred in 44% of patients with post-
herpetic neuralgia and 41% of patients with HIV-associ-
ated neuropathy. All of the mentioned studies have
observation period of 2–12 weeks as in our study. In this
context, our study shows a striking reduction of neuropa-
thy-related symptoms after application of high-dose 8%
capsaicin with symptoms relief up to 97% after 12 weeks.
Certain authors attempted to determine possible pre-
dictors of treatment response to treatment with high-dose
8% capsaicin. Katz et al. [18] found that baseline pain
intensity score B4, absence of allodynia and presence of
hypoesthesia are related to sustained response to capsaicin
treatment. Mainka et al. [19] found that the presence of
hyperalgesia predicts analgesic efficacy of high-dose cap-
saicin. Our study group unfortunately was too small to
calculate possible predictors of treatment response.
Our study has certain limitations. Firstly, our study pop-
ulationwas only 18 patients andwas limited by the amount of
founding for off-label use of patches that we were able to
provide. Second limitation that our study group was not
examined by standardized questionnaires such as Brief Pain
Inventory orMcGill Pain inventory. On the other hand, all of
patients were examined by a board-certified neurologist.
This raw data showmuchmore detailed signs and symptoms
specific to neuropathic patients. Most of the standardized
questionnaires do not include such specific symptoms. We
are confident that in term of presenting neuropathic patients
symptoms detailed neurological examinations have deeper
significance. Thirdly, we were able to present only obser-
vation period of 12 weeks, not being able to determine the
total length of effect of the treatment. We are planning to do
so in further studies.
To the best of our knowledge this is the first study
attempting to determine the use of high-dose 8% capsaicin
patch in treatment of chemotherapy-induced peripheral
neuropathy.
Table 2 Comparison of patients according to dosage after which symptoms occurred
Initial symptoms after\648.07 mg/m2 Initial symptoms after C648.07 mg/m2
n = 6 n = 12 p value
Age, years (SD) 63.17 ± 6.55 62.41 ± 9.24 0.86
Female (%) 5(83.33) 7(58.33) 0.29
Initial pain level 7.67 ± 0.51 7.17 ± 1.34 0.40
Pain after 1 day, NRS 5.50 ± 1.57 4.75 ± 1.36 0.30
Pain after 8 days, NRS 3.83 ± 1.47 2.25 ± 1.14 0.02
Pain after 8 weeks, NRS 2.50 ± 1.87 1.25 ± 1.29 0.11
Pain after 12 weeks, NRS 1.16 ± 1/32 0.25 ± 0.45 0.04
Pain reduction after 1 day, % (SD) 27.98 ± 19.74 33.44 ± 15.20 0.52
Pain reduction after 8 days, % (SD) 49.40 ± 20.34 69.55 ± 12.09 0.02
Pain reduction after 8 weeks, % (SD) 66.67 ± 24.99 84.21 ± 16.20 0.09
Pain reduction after 12 weeks, % (SD) 83.93 ± 18.59 96.96 ± 5.56 0.04
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